Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,200.90 24.93 0.78%
FTSE 100 6,717.10 42.36 0.63%
DAX 9,618.01 73.82 0.77%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

NYSE Euronext Welcomes AbbVie to Its European and U.S. Markets


PR Newswire/Les Echos/

NYSE Euronext Welcomes AbbVie to Its European and U.S. Markets

Global biopharmaceutical company cross-lists and rings the Opening Bell SM in New York

NEW YORK and PARIS, Jan. 2, 2013 -- Today, AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company formed in 2013 following separation from Abbott (NYSE: ABT), marked its cross-listing on NYSE Euronext (NYX) markets in Europe and the United States by ringing the Opening Bell in New York. AbbVie used the streamlined, cost-effective Fast Path process to cross-list in Europe, making it the fifteenth company to take advantage of this procedure since it was made available by NYSE Euronext in 2008.

AbbVie's Common Stock was admitted to listing and trading on the NYSE Euronext markets by direct listing of its approximately 1.58 billion existing shares making up its capital and representing a market capitalization of 40 billion/ $54 billion.

Richard Gonzalez, CEO of AbbVie, said: "Today AbbVie launches with an outstanding portfolio, a solid pipeline and enthusiastic people who will serve patients and deliver growth. With those assets and a relentless focus on innovation we intend to create significant value for our shareholders."

"We welcome AbbVie to the community of NYSE Euronext listed companies and applaud its decision to cross-list on our European and U.S. markets which will rein force its global identity", added Scott Cutler, EVP, Head of Global Listings at NYSE Euronext. "This is the beginning of a lasting relationship that will give AbbVie the benefits of the highest levels of service, liquidity and transparency available through NYSE Euronext."

Notes to Editors:

1 Background about cross-listing on NYSE Euronext European markets

* NYSE Euronext is the first and only exchange group to offer a truly global


    cross-market listing, trading and visibility platform, providing 
    cost-effective, convenient access to investors and business partners in 

the US and in Europe. * NYSE Euronext is the first exchange group to offer companies the ability

to trade and raise capital in and $ and reach investors and constituents

directly across continents and multiple time zones, regions and countries. * Valuable for any company looking to enhance its global profile, support


    an international business or expand its non-US investor base, a Fast Path 
    listing provides an easy, cost-effective way to gain a European trading 
    presence. Euronext regulators accept documentation, previously filed with 
    the SEC, to satisfy the EU Prospectus Directive. With Fast Path, a company 
    avoids the need to draft and translate a separate prospectus in order to
    be admitted to trading. Documents filed with the SEC serve as the primary 
    component to obtain approval from the competent Euronext regulator. The 
    SEC documentation is combined with a summary "wrapper", addressing any 
    additional European and local requirements, forming the company's 

European prospectus.

2 Executives from AbbVie rang the Opening Bell at the New York Stock Exchange on Wednesday, January 2, 2013.

Contacts:

AbbVie Adelle Infante: 847-938-8745

NYSE Euronext Caroline Tourrier: +33 (0)1 49 27 10 82

About AbbVie AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 21,000 people worldwide and market medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.com/. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

About NYSE Euronext NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers a comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com/.

CONTACT - Media: CONTACT - Investor Relations: nyx.com

Amsterdam +31.20.550.4488 Brussels +32.2.509.1392 New York +1.212.656.5700 Lisbon +351.217.900.029 London +44.20.7379.2789 New York +1.212.656.2411 Paris +33.1.49.27.11.33

Please follow us at: Exchanges Blog Faoebook LinkedIn Twitter

SOURCE AbbVie Inc.

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Jan/03/2013 08:25 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement